A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).

@article{Owonikoko2015AP1,
  title={A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).},
  author={Taofeek K Owonikoko and Suzanne E Dahlberg and Saad A Khan and David E Gerber and Jonathan E. Dowell and Rebecca Anne Moss and Chandra Prakash Belani and Christine L. Hann and C. Gautam Aggarwal and Suresh S Ramalingam},
  journal={Lung cancer},
  year={2015},
  volume={89 1},
  pages={
          66-70
        }
}
OBJECTIVES Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. MATERIALS AND METHODS The study employed the 3+3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75 mg/m(2) on day 1) and E (100mg/m(2) on days 1-3) in a 21-day cycle. The starting dose of V was 60 mg… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Research progress in the treatment of small cell lung cancer

  • Journal of Cancer
  • 2017
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Targeting DNA damage in SCLC.

VIEW 1 EXCERPT
CITES RESULTS

Similar Papers

Loading similar papers…